EUCTR2012-003504-12-DK进行中（未招募）1 期
Glucocorticoid-induced inhibition of IGF-I activity: exploration of underlying mechanisms.
Medical Research Laboratory, Clinical institute of Medicine, Aarhus University Hospital0 个研究点开始时间: 2012年10月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Signed and dated informed consent
- •Healthy subjects
- •Age 20-30 years
- •BMI 19-26 kg/m2
- •normal HbA1c
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Suspected or known allergy to the trial drug or similar medications.
- •Known current illness including diabetes mellitus, ischemic heart disease or cardiac arrhytmia.
- •Daily drug intake (excluding OCT preparations).
- •Known or previous mental illness.
- •Current participation or previous participation in experiments using ionizing radiation for a year prior to inclusion in this study.
- •participation in a larger X-ray examinations in trial period
研究者
相似试验
已完成
2 期
Glucocorticoid Induced Whole Body CatabolismeWhole Body Catabolisme Induced by GlucocorticoidsNCT01762540University of Aarhus19
尚未招募
不适用
Effect of low dose steroids on blood glucose and risk of heart diseaseInsulin sensitivitycardiovascular riskenergy metabolisminflammatory arthritisCardiovascular - Coronary heart diseaseMetabolic and Endocrine - DiabetesInflammatory and Immune System - Rheumatoid arthritisACTRN12612000540819Morton Burt36
进行中（未招募）
1 期
Prevention of Glucocorticoid induced impairment of bone metabolism – A Randomized, Placebo-Controlled, Single Centre Clinical TrialOral glucocorticoid (GC) therapy leads to a rapid and profound effects on bone metabolism.The gut microbiota is involved in regulating bone metabolism.Lactobacillus reuteri (LR) has been shown to have probiotic, health-promoting effects.The aim of this randomized, double-blind, placebo-controlled trial is to investigate if daily supplementation with LR, compared to placebo, can prevent the negative effects of oral GC on bone turnover and on blood glucose regulation in healthy young adults.EUCTR2021-000275-36-SESahlgrenska University Hospital50
尚未招募
不适用
Effect of Rosiglitazone on Glucocorticoid-stimulated 11betaHSD-1 Activity in Skeletal MuscleType 2 diabetesMetabolic and Endocrine - DiabetesACTRN12606000200583Dr Warrick Inder20
进行中（未招募）
1 期
A study to assess whether a product call relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo.Endogenous Cushing syndromeMedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860EUCTR2018-003096-35-ESCorcept Therapeutics Incorporated130